

# SAHA Patient: IV vs ORAL (200 mg/dose)

**Patient #**

**1-OS-200**

## Week 1

## Week 2

## IV

# ORAL

## Marker

+

1

**Pre**

## Post

**Pre**

### Post-2hrs


### Post-4hrs

 $\alpha$ -AcH4

# Coomassie blue

FIG. 1

**Protocol 01-021 (ORAL SAHA) ARM A: SOLID  
TUMOR PATIENTS Cohort I (200 mg/dose)**



**FIG. 2**

# SAHA Patients: ORAL /Cohort I (200 mg/dose)




FIG. 3

**Protocol 01-021 (ORAL SAHA)**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort I (200 mg/dose)**






FIG. 4

**Protocol 01-021 (ORAL SAHA)**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort IIa (400 mg/dose)**  
**7-OS-400                      8-OS-400**



12/19/01

**9-OS-400**



12/27/01

FIG. 5

# SAHA Patients: ORAL/Cohort II (400 mg/dose)




FIG. 6

**Pr tocol 01-021 (ORAL SAHA )**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort IIa (400 mg/dose)**




FIG. 7

# SAHA Patients: ORAL/Cohort II (400 mg/dose)





FIG. 8

# Oral 200 mg vs. 400 mg (Fasting)

Oral dose on Cycle 1 Day 8




Figure 9A

# Oral 200 mg vs. 400 mg (no-fasting)

Oral Dose on Cycle 1 Day 9




Figure 9B

# IV 200 mg vs. 400 mg

IV Dose on Cycle 1 Day 1





Figure 9C

# Apparent Half-life of the Oral Dose


---



3/4/2003

Figure 10

# AUC of the Oral Dose



■ = 200 mg group (n=3-5); □ = 400 mg group (n=5-10)

3/4/2003

Figure 11

# Bioavailability





Figure 12

CONFIDENTIAL


ATON  
PHARMA


Figure 13

A




B





A



B

Figure 14

CONFIDENTIAL

A




B

Figure 15



Pre-Therapy

2 months Post SAHA



A

B

Figure 16

CONFIDENTIAL

ATON  
PHARMA